CompletedNot Applicable

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

Austria, Belgium, Czechia315 participantsStarted 2013-09

Plain-language summary

The purpose of this study is to look at the long term safety profile of Orfadin treatment in patients suffering from hereditary tyrosinemia type 1 (HT-1). Patients included in the study will use Orfadin according to normal clinical practice.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All HT-1 patients receiving Orfadin treatment are eligible for entry. Exclusion Criteria: * No exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Occurrence of Adverse events related to hepatic function

Timeframe: from 2005

Occurrence of Adverse events related to renal function

Timeframe: from 2005

Occurrence of Adverse events related to Ophthalmological function

Timeframe: from 2005

Occurrence of Adverse events related to hematological function

Timeframe: from 2005

Occurrence of Adverse events related to cognitive developmental function

Timeframe: from 2005

Trial details

NCT IDNCT02320084

SponsorSwedish Orphan Biovitrum

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-09-30

View on ClinicalTrials.gov More Hereditary Tyrosinemia, Type I trials

What they're measuring

Occurrence of Adverse events related to hepatic function

Timeframe: from 2005

Occurrence of Adverse events related to renal function

Timeframe: from 2005

Occurrence of Adverse events related to Ophthalmological function

Timeframe: from 2005

Occurrence of Adverse events related to hematological function

Timeframe: from 2005

Occurrence of Adverse events related to cognitive developmental function

Timeframe: from 2005